NASDAQ:FENC - Fennec Pharmaceuticals Stock Price, Forecast & News

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Fennec Pharmaceuticals Inc (NASDAQ:FENC) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.11. View Fennec Pharmaceuticals' Earnings History.

Fennec Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Fennec Pharmaceuticals.

2 brokerages have issued 12-month price objectives for Fennec Pharmaceuticals' stock. Their forecasts range from $16.00 to $17.00. On average, they anticipate Fennec Pharmaceuticals' stock price to reach $16.50 in the next year. This suggests a possible upside of 167.0% from the stock's current price. View Analyst Price Targets for Fennec Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fennec Pharmaceuticals.

Press coverage about FENC stock has trended positive on Monday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fennec Pharmaceuticals earned a news impact score of 3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Fennec Pharmaceuticals.

Fennec Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 469,400 shares, an increase of 10.4% from the December 15th total of 425,000 shares. Based on an average daily volume of 29,300 shares, the short-interest ratio is presently 16.0 days. Approximately 2.9% of the company's stock are sold short. View Fennec Pharmaceuticals' Current Options Chain.

Some companies that are related to Fennec Pharmaceuticals include Translate Bio (TBIO), Adaptimmune Therapeutics (ADAP), Aptose Biosciences (APTO), BioCryst Pharmaceuticals (BCRX), Gritstone Oncology (GRTS), Cabaletta Bio (CABA), PDL BioPharma (PDLI), Harpoon Therapeutics (HARP), Eiger Biopharmaceuticals (EIGR), Tcr2 Therapeutics (TCRR), Cellular Biomedicine Group (CBMG), Scholar Rock (SRRK), Compugen (CGEN), CASI Pharmaceuticals (CASI) and Sutro Biopharma (STRO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Iovance Biotherapeutics (IOVA), Amarin (AMRN), Fate Therapeutics (FATE), Karyopharm Therapeutics (KPTI), Allena Pharmaceuticals (ALNA), Coherus Biosciences (CHRS), Denali Therapeutics (DNLI), Amicus Therapeutics (FOLD), Pieris Pharmaceuticals (PIRS) and Aptose Biosciences (APTO).

Fennec Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.12%). View Institutional Ownership Trends for Fennec Pharmaceuticals.

FENC stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Fennec Pharmaceuticals.

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FENC stock can currently be purchased for approximately $6.18.

Fennec Pharmaceuticals has a market capitalization of $122.98 million. The company earns $-9,890,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. View Additional Information About Fennec Pharmaceuticals.

The official website for Fennec Pharmaceuticals is http://www.fennecpharma.com/.

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.